Ketamine therapy: the compliance architecture before the first infusion

The line that actually matters: an off-label controlled substance

What separates a compliant ketamine practice from a risky one starts with a fact many programs gloss over: racemic ketamine for mood is used off-label, and it is a Schedule III controlled substance. Unlike buprenorphine for opioid use disorder — which, since 2023, any prescriber with Schedule III authority and a current DEA registration may provide office-based after a one-time training attestation 1Ref 1Substance Abuse and Mental Health Services Administration (2026).Buprenorphine.That since 2023 any prescriber with Schedule III authority and a current DEA registration may treat opioid use disorder office-based after a one-time training attestation, contrasted with ketamine's lack of any federal treatment framework. — ketamine has no federal treatment framework. The compliance scaffold is entirely yours to build.

Off-label use of an approved drug is legal and common, but it raises the bar on documentation, consent, and clinical justification, because you cannot lean on an FDA-approved indication to defend the choice. This page is about racemic ketamine given in your office, where the guardrails are the ones you install — and where the gap between a defensible program and a risky one is almost never the clinical protocol itself.

Your DEA registration and the records behind it

Everything about a ketamine program routes through your DEA registration. The DEA's Diversion Control Division administers practitioner registration and renewal, the electronic-prescribing rules for controlled substances, and the recordkeeping and inventory requirements that follow a Schedule III drug into your office 2Ref 2Drug Enforcement Administration (2026).Diversion Control Division.That the DEA Diversion Control Division administers practitioner registration and renewal, EPCS requirements, and the controlled-substance recordkeeping and inventory rules that govern an in-office ketamine program.. Those records are not optional paperwork — they are the first thing an inspection asks for, and gaps in them are what turn a clinical program into an enforcement problem.

Keep these current and reconcilable at all times 2Ref 2Drug Enforcement Administration (2026).Diversion Control Division.That the DEA Diversion Control Division administers practitioner registration and renewal, EPCS requirements, and the controlled-substance recordkeeping and inventory rules that govern an in-office ketamine program.:

• Registration. A DEA registration matched to the schedule and the practice location, renewed on its cycle.
• Ordering and receipt records. A clean trail of what controlled stock came in, from whom, and when.
• Inventory. A dated count you can reproduce, with the periodic inventory the rules require.
• Storage and access. Secure storage and a short, documented list of who can reach it.
• Disposal. A compliant record of what was wasted and how.

If you administer in-office, the drug is physically in your custody, which raises the diversion stakes well above those of a prescribe-and-send practice.

The PDMP check before you prescribe

Before prescribing a controlled substance, check your state's prescription drug monitoring program. Every state runs a PDMP, and most now mandate a query before controlled-substance prescribing, though the trigger and frequency vary by state 3Ref 3PDMP Training and Technical Assistance Center (2026).Prescription Drug Monitoring Program Training and Technical Assistance Center.That every state operates a PDMP and most mandate a query before controlled-substance prescribing, with the trigger and frequency varying by state.. The PDMP TTAC maintains the state-by-state profiles, but the binding rule is your own state's — so confirm what yours requires and when, and document that you checked.

For an in-office administration model this is less about catching a doctor-shopping pattern at the pharmacy counter and more about a defensible record: a documented PDMP check ties your controlled-substance decision to a standard practice reviewers recognize. Build the query into the visit workflow so it happens every time, not only when something feels off.

Informed consent for an off-label use

Informed consent for an off-label use carries more weight than a routine consent form, and a common convention among careful programs is to make the off-label status explicit in writing. The consent conversation typically names that the use is not an FDA-approved indication, the known risks and the monitoring involved, the alternatives, and what happens between and after sessions. Documenting that discussion is how the clinical judgment behind an off-label choice becomes defensible.

Many programs pair the consent with a written expectations document — the same family as the prescription agreements used for other controlled substances, covering monitoring, missed sessions, and the conditions under which treatment stops. Keep the signed consent and the agreement in the chart, and re-consent when the plan materially changes rather than treating the first signature as permanent.

Scope of practice and who can prescribe

Who may prescribe and administer ketamine, and under what supervision, depends on your license type and your state — this is genuinely jurisdiction-variable, so treat any single answer with suspicion. A physician, an appropriately authorized nurse practitioner, or a physician assistant may each face different scope and supervision rules, and some states require a collaborative or supervisory arrangement for the setting. Confirm the rule with your own licensing board before you rely on it.

If you bring on a prescriber or work under a supervising physician, the mechanics of your first np or pa and the collaborative agreement are where scope rules bite hardest — including renewal cadence and documentation. Cross-state practice adds another layer: the aprn gap in the nursing compact means multistate privileges do not cover every role, so a program that treats patients across state lines has to check each state separately.

The safety envelope and the office around it

An in-office administration program is a small clinical setting, and the boilerplate of running one applies to you as fully as to a hospital. That means a monitoring plan during and after administration, a plan for an acute adverse event, and the workplace-safety obligations that osha and the solo office still impose even on a practice of one. None of this is optional because you are small; it is the envelope that makes the clinical service safe to offer.

Two more disciplines protect you on the business side. Keep the practice's money and the drug's money in clean separation from day one, so acquisition, administration, and billing each stand on their own records. And advertise honestly: describing an off-label treatment as a proven cure invites both board and regulator attention, where a plain description of what the treatment is and is not draws far less. Compliance here is mostly the sum of small habits done every time.